Provided by Tiger Trade Technology Pte. Ltd.

Atea Pharmaceuticals, Inc.

3.18
-0.0400-1.24%
Volume:216.05K
Turnover:691.38K
Market Cap:248.44M
PE:-1.80
High:3.27
Open:3.22
Low:3.16
Close:3.22
52wk High:4.02
52wk Low:2.46
Shares:78.13M
Float Shares:60.01M
Volume Ratio:0.61
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7696
EPS(LYR):-1.9983
ROE:-37.98%
ROA:-23.86%
PB:0.79
PE(LYR):-1.59

Loading ...

Nano Dimension And 2 Other Penny Stocks With Promising Potential

Simply Wall St.
·
16 hours ago

Atea Pharmaceuticals to Present at Evercore Healthcare Conference

Reuters
·
Nov 19

3 Promising Penny Stocks With Market Caps As Low As $200M

Simply Wall St.
·
Nov 13

Atea Pharmaceuticals Advances Antiviral Programs with New Data

TIPRANKS
·
Nov 13

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Announces Progress in Hepatitis C and E Programs

Reuters
·
Nov 13

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13

Atea Pharmaceuticals announces presentation of data on BEM, RZR

TIPRANKS
·
Nov 07

Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment

Reuters
·
Nov 07

Atea Pharmaceuticals Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Nov 05

Atea Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Reuters
·
Nov 04

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

GlobeNewswire
·
Oct 22

Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

TIPRANKS
·
Oct 07

Atea Pharmaceuticals Announces Promising New Data for Bemnifosbuvir and Ruzasvir Combination in Hepatitis C Treatment at The Liver Meeting® 2025

Reuters
·
Oct 07

Atea Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 02

Atea Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Atea Pharmaceuticals Q2 EPS USD -0.44

THOMSON REUTERS
·
Aug 08

Atea Pharmaceuticals Q2 EPS $(0.44) Misses $(0.43) Estimate

Benzinga
·
Aug 08

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 08

Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Aug 06

Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Aug 01